Skip to main content
. 2014 Sep 30;6(4):2035–2048. doi: 10.3390/cancers6042035

Figure 1.

Figure 1

Time to progression in G (gefitinib) and GIL-2 (gefitinib and IL-2) groups (p = not significant).